Copilot question for those that may not know about the Acute...

Copilot question for those that may not know about the Acute Myloid Luekemia (AML) diesase and market. The best thing about this announcement is the fast tracking of RC220 drug into sick people that need it! A great outcome!

Here’s a summary of the key information regarding Acute Myeloid Leukemia (AML) and its global treatment market:

• Global Prevalence: AML accounted for 23.1% of total leukemia cases worldwide in 2017, with an age-standardized incidence rate (ASIR) of 1.54 per 100,000 people¹.
• Market Value: The global AML treatment market was valued at nearly $3.5 billion in 2022 and is expected to grow to $6.1 billion by 2028 with a compound annual growth rate (CAGR) of 10.0%².
• Treatment Advantages: The US FDA Orphan Drug Designation (ODD) provides benefits like tax credits, fee waivers, and market exclusivity, which can be significant for companies like Race Oncology in developing treatments like bisantrene¹.
• Race Oncology’s Progress: Race Oncology has received ODD for its RC220 bisantrene drug product for AML and is working towards opening an FDA IND in 2025, with IP protection expected to extend to 2044¹.

This information reflects the significant impact of AML on public health and the substantial market for its treatment. Race Oncology’s efforts in developing bisantrene highlight the ongoing advancements in AML therapy.

Question: What is the current Outlook for a Patient with AML?

The current outlook for a patient with Acute Myeloid Leukemia (AML) varies based on several factors, including age, genetic changes, and how advanced the AML is at diagnosis. Here are some key points:

• Overall Survival: The 5-year survival rate for AML is around 24% to 29.5%¹².
• Age Factor: Younger patients generally have a better prognosis. For example, almost 60% of patients under 40 survive for 5 years or more after diagnosis³.
• Treatment Response: Advancements in treatments are improving survival rates, and many patients go into remission with chemotherapy².
• Children’s Prognosis: Children with AML have a higher 5-year survival rate of 65% to 70%².

It’s important to consult with a healthcare professional for personalized information.